Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

My little theory is that the concept of “imprinting” in psychology can just as easily be applied to programming: Much as a baby goose decides that the first moving life-form it encounters is its ...

WASHINGTON — As part of next steps for the Janus Program, the Department of the Army has selected nine installations for consideration in which to site microreactor power plants, and the Defense ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

The deployment makes it possible for advertisers to execute video ad campaigns in a CTV-like manner using traditional TV ad inventory, the two companies said. When you purchase through links on our ...

The Trump Administration says it will end a $7 billion program to help low-income households and communities get access to affordable solar energy. The move is part of President Trump's effort to ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – Rallybio Corporation (Nasdaq: RLYB), a ...